OAM
TEVA icon

Oppenheimer Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Oppenheimer Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,806
Closed -$138K – 1653
2019
Q1 		$138K Buy
8,806
+8,367
+1,906% +$148K ﹤0.01% 1134
2018
Q4 		$7K Buy
+439
New +$9K ﹤0.01% 1535
2018
Q1 		– Sell
-23,568
Closed -$415K – 1177
2017
Q4 		$415K Hold
23,568
– – 0.01% 836
2017
Q3 		$415K Sell
23,568
-2,858
-11% -$64.3K 0.01% 840
2017
Q2 		$878K Buy
26,426
+5,468
+26% +$169K 0.02% 629
2017
Q1 		$672K Buy
+20,958
New +$715K 0.02% 706

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oppenheimer Asset Management's TEVA Position: Q2 2019 in Review

Oppenheimer Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 8,806 shares — an estimated $138K sold.

Oppenheimer Asset Management first reported a position in TEVA in Q1 2017 and held it in 6 quarters. The position peaked at $878K in Q2 2017. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Oppenheimer Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Oppenheimer Asset Management sold 8,806 Teva Pharmaceuticals shares in Q2 2019, an estimated $138K.
  • Oppenheimer Asset Management first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 6 quarters.
  • Oppenheimer Asset Management's Teva Pharmaceuticals position peaked at $878K in Q2 2017.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Oppenheimer Asset Management's 13F filing for Q2 2019, filed 9 Aug 2019.